Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

SamuraiPlayers May. 21 at 9:27 PM

Have you missed the recent 800%+ runners?! Make sure to keep ticker EZRA on watch ! Taking a position at these levels. I really hope the shorts get squeezed out hard. EZRA has barely 530k shares outstanding. We saw a mini spike earlier.. Would not be surprised if it runs wild soon. The key is to buy before the crowd 💎 Calls on $BABA $INTC $PFE --

0 · Reply

Micheal_Pothead May. 21 at 7:49 PM

$PFE okay I’m getting worried now

1 · Reply

PFElinepfrenzy1990 May. 21 at 7:41 PM

$PFE - Impressive volumen’t

1 · Reply

Find_the_Cure May. 21 at 7:34 PM

$PFE Trash Hauling needed here

0 · Reply

nimii May. 21 at 6:50 PM

$PFE give me 28

0 · Reply

pasuny May. 21 at 6:05 PM

$PFE You guys are like, we are up 0.3%! OMG! This is the best day of my life! Pathetic.

1 · Reply

JBS_84 May. 21 at 5:11 PM

$PFE A few minutes ago there was a huge red volume bar. This is one of many examples of what I refer to as games. Look it up. They will hide large buys in these red volume bars to try and fool you. It was mostly a million dollar order at 25.8. But at a glance retail will see it as major selling pressure and in turn sell their shares probably directly to some institutional trader. Keep in mind the institutions make money off of retail fools. Don't be one of them. Look for these games. Think like they do

0 · Reply

BillionerOfKing May. 21 at 4:55 PM

$PFE Current Stock Price: $25.81 Contracts to trade: $26.0 PFE May 22 2026 Call Entry: $0.07 Exit: $0.12 ROI: 71% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Mrdrifter May. 21 at 3:56 PM

$PFE MACD cross and perched on the averages. Looks like it wants 26.40s soon

1 · Reply

JBS_84 May. 21 at 3:42 PM

$PFE Don't fall for games here. Daily macd is about to cross over and it's riding crucial moving averages. Games will probably be played until next week to wash out as much retail as possible.

1 · Reply

Moderately bullish activity in Pfizer with shares up 0.41%

May 20, 2026, 9:00 AM EDT - 1 day ago

Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer

2026-05-20T09:30:10.000Z - 1 day ago

Pfizer announces pneumococcal conjugate vaccine candidate data

May 20, 2026, 5:08 AM EDT - 1 day ago

Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial

May 20, 2026, 5:05 AM EDT - 1 day ago

Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results

2026-05-18T17:01:06.000Z - 3 days ago

PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’

AZN LLY NVO SNY

May 18, 2026, 8:00 AM EDT - 3 days ago

Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026

May 14, 2026, 2:22 PM EDT - 7 days ago

Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch

DGX MO CL

2026-05-14T17:29:38.000Z - 7 days ago

Pfizer price target raised to $26 from $25 at Wolfe Research

2026-05-13T19:23:39.000Z - 8 days ago

Mixed options sentiment in Pfizer with shares up 0.48%

2026-05-13T19:22:15.000Z - 8 days ago

Arvinas price target raised to $16 from $14 at BofA

ARVN RIGL

2026-05-13T11:10:14.000Z - 8 days ago

Pfizer says EC grants marketing approval to expand indication for Hympavzi

May 13, 2026, 6:45 AM EDT - 8 days ago

European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors

2026-05-13T07:12:25.000Z - 8 days ago

Pfizer (PFE) Delivered a Solid Q1. The Patent Cliff Keeps Me Bearish

LLY NVO

2026-05-12T17:45:03.000Z - 9 days ago

H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’

ARVN RIGL

2026-05-12T16:35:26.000Z - 9 days ago

Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu

ARVN RIGL

2026-05-12T13:02:04.000Z - 9 days ago

Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer

ARVN RIGL

May 12, 2026, 8:00 AM EDT - 9 days ago

Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug

ARVN RIGL

May 12, 2026, 7:00 AM EDT - 9 days ago

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

ARVN

May 5, 2026, 4:09 PM EDT - 16 days ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:02 PM EDT - 16 days ago

Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 11:30 AM EDT - 16 days ago

3 Dividend Stocks for May 2026

SYY WSO

May 5, 2026, 10:00 AM EDT - 16 days ago

Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 16 days ago

Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 16 days ago

Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 16 days ago

Pfizer Slides: Q1 2026

May 5, 2026, 8:35 AM EDT - 16 days ago

Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 7:23 AM EDT - 16 days ago

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

May 5, 2026, 7:06 AM EDT - 16 days ago

Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates

May 5, 2026, 7:05 AM EDT - 16 days ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS

May 5, 2026, 6:55 AM EDT - 16 days ago

Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth

May 5, 2026, 6:51 AM EDT - 16 days ago

Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis

May 5, 2026, 6:45 AM EDT - 16 days ago

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

May 1, 2026, 12:37 PM EDT - 20 days ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN

Apr 29, 2026, 7:42 AM EDT - 22 days ago

Pfizer's blood cancer drug meets main goal in late-stage trial

$Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma$

Apr 29, 2026, 6:45 AM EDT - 22 days ago

Pfizer's ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

Apr 28, 2026, 10:41 AM EDT - 23 days ago

Pfizer secures deals to keep heart drug free of generic rivals until 2031

Apr 28, 2026, 10:17 AM EDT - 23 days ago

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

Apr 24, 2026, 8:36 AM EDT - 27 days ago

Bristol Myers, Pfizer to offer blockbuster blood thinner through Mark Cuban's online pharmacy

BMY

Apr 23, 2026, 9:00 AM EDT - 4 weeks ago

Pfizer Transcript: AGM 2026

Apr 22, 2026, 4:45 PM EDT - 4 weeks ago

Pfizer Declares Second-Quarter 2026 Dividend

Apr 22, 2026, 5:18 AM EDT - 4 weeks ago

Pfizer GLP-1 weight loss drug available for pre-order in China

Apr 21, 2026, 11:51 AM EDT - 4 weeks ago

Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026

Apr 20, 2026, 3:05 PM EDT - 4 weeks ago

Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says

Apr 20, 2026, 6:45 AM EDT - 4 weeks ago

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Apr 16, 2026, 1:01 PM EDT - 5 weeks ago

The Big 3: PFE, V, SYF

SYF V

Apr 10, 2026, 11:00 PM EDT - 5 weeks ago

Big Pharma Is Turning to China for the Newest Drug Ideas

Apr 9, 2026, 10:00 AM EDT - 6 weeks ago

Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders

Apr 2, 2026, 11:14 AM EDT - 7 weeks ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO LLY

Apr 1, 2026, 11:39 AM EDT - 7 weeks ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

BNTX

Apr 1, 2026, 10:13 AM EDT - 7 weeks ago

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Mar 30, 2026, 10:44 AM EDT - 7 weeks ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PPH

Mar 24, 2026, 10:00 AM EDT - 2 months ago

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Mar 23, 2026, 12:46 PM EDT - 2 months ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

VALN

Mar 23, 2026, 9:36 AM EDT - 2 months ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

VALN

Mar 23, 2026, 7:07 AM EDT - 2 months ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

VALN

Mar 23, 2026, 7:02 AM EDT - 2 months ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Mar 23, 2026, 6:47 AM EDT - 2 months ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Mar 23, 2026, 6:45 AM EDT - 2 months ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

Mar 22, 2026, 9:45 AM EDT - 2 months ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Mar 20, 2026, 4:30 PM EDT - 2 months ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 19, 2026, 6:45 AM EDT - 2 months ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Mar 17, 2026, 7:49 AM EDT - 2 months ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 6:45 AM EDT - 2 months ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Pfizer Proxy statement: Proxy Filing

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Pfizer Proxy statement: Proxy Filing

Mar 9, 2026, 7:27 AM EDT - 2 months ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

SamuraiPlayers May. 21 at 9:27 PM

0 · Reply

Micheal_Pothead May. 21 at 7:49 PM

$PFE okay I’m getting worried now

1 · Reply

PFElinepfrenzy1990 May. 21 at 7:41 PM

$PFE - Impressive volumen’t

1 · Reply

Find_the_Cure May. 21 at 7:34 PM

$PFE Trash Hauling needed here

0 · Reply

nimii May. 21 at 6:50 PM

$PFE give me 28

0 · Reply

pasuny May. 21 at 6:05 PM

$PFE You guys are like, we are up 0.3%! OMG! This is the best day of my life! Pathetic.

1 · Reply

JBS_84 May. 21 at 5:11 PM

0 · Reply

BillionerOfKing May. 21 at 4:55 PM

0 · Reply

Mrdrifter May. 21 at 3:56 PM

$PFE MACD cross and perched on the averages. Looks like it wants 26.40s soon

1 · Reply

JBS_84 May. 21 at 3:42 PM

$PFE Don't fall for games here. Daily macd is about to cross over and it's riding crucial moving averages. Games will probably be played until next week to wash out as much retail as possible.

1 · Reply

pasuny May. 21 at 3:25 PM

$PFE Jesus Pho King Christ... The CEO in human history!!! We gotta gotta do something about it!!! Fire the CEO!!!

0 · Reply

55X_ROI_Q1_2026 May. 21 at 2:57 PM

$SLS $LLY $PFE these are the precise days to be loading..

0 · Reply

pasuny May. 21 at 2:37 PM

$PFE Miserable company... So pathetic...

0 · Reply

55X_ROI_Q1_2026 May. 21 at 2:36 PM

$SLS $LLY $PFE THE MOMENT THE 80th EVENT PR is announced, we ALL WILL WISH WE BOUGHT MORE SHARES RIGHT NOW . . . Fact.

0 · Reply

BioRich May. 21 at 2:36 PM

$SGP Excited to be the 35th follower to this ticker. One of our Team highlighted this gem which has an insane institution backing with some of the biggest players in the market. Insane All-Star line-up. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI $PFE $MRK $BMY

0 · Reply

55X_ROI_Q1_2026 May. 21 at 2:33 PM

$SLS $LLY $PFE

0 · Reply

55X_ROI_Q1_2026 May. 21 at 2:22 PM

$SLS $LLY $PFE it is not complicated, the Share price will be climbing until we see the Imminently due 80th Event PR and then the share price will Launch - ahead of the Topline Registrational Phase 3 Results and ensuing Ballistic Verticality.

0 · Reply

BullMaven May. 21 at 1:58 PM

$PFE adding 500

0 · Reply

renoH4 May. 21 at 12:42 PM

$PFE If Pfizer settls fast with Arbutus Biopharma they could fight together against EBOLA ! Background: Arbutus LNP Technology Was Ahead of Its Time Interestingly, Tekmira/Arbutus was one of the early pioneers of LNP technology—a technology that later became crucial for mRNA vaccines as well. The expertise gained from these Ebola programs indirectly contributed to subsequent RNA-based therapeutics and vaccine platforms. Theoretically, it would be possible to develop an adapted RNAi formulation targeting a new Ebola strain. Today, this could be accomplished even faster than it was in 2014.

0 · Reply

jacobmintz May. 21 at 9:40 AM

Cabot Options Trader Call Buying Activity - $NOK $META $PFE $CSCO $AS

0 · Reply

sam92 May. 21 at 9:14 AM

$PFE https://www.stocktitan.net/news/PFE/pfizer-advances-pivotal-pediatric-pneumococcal-vaccine-program-b6z4hz1vw4zi.html

0 · Reply

55X_ROI_Q1_2026 May. 21 at 3:09 AM

$SLS $LLY $PFE Share price will continue climbing until we see the Imminently due 80th Event PR and then the share price will Launch - ahead of the Topline Registrational Phase 3 Results.

0 · Reply

Market Cap	146.25B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	8.28
Forward PE	8.48
Profit Margin	12.42%
Debt to Equity Ratio	0.71

Volume	20,147,289
Avg Vol	37,599,949
Day's Range	N/A - N/A
Shares Out	5.70B
Stochastic %K	60%
Beta	0.35
Analysts	Sell
Price Target	$29.28